Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer

Jun-jie Ma; Hui-ping Liu

doi:10.1007/s11655-016-2511-4

Your Location：

Home >

Browse articles >

Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer

Updated：2021-08-27

- Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer
- Chinese Journal of Integrative Medicine Vol. 23, Issue 7, Pages: 504-509(2017)
- Affiliations：
  
  1. College of Basic Medicine, Nanjing University of Chinese Medicine,Nanjing,China
  2. Department of Oncology, Jiangsu Shuyang Hospital of Traditional Chinese Medicine,Jiangsu Province,Suqian,China
  3. Department of Thoracic Surgery, Nanjing BenQ Hospital Affiliated to Nanjing Medical University,Nanjing,China
- Author bio：
- Funds：
  
  Supported by the 2011 National Key Specialty Construction of Clinical Projects of China, Science and Technology Projects of Traditional Chinese Medicine Bureau in Jiangsu Province of China (No. LB13042)
- DOI：10.1007/s11655-016-2511-4
  CLC：
- Published：2017，
  
  Published Online：2 August 2016，
Scan for full text
Ma, Jj., Liu, Hp. Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer., Chin. J. Integr. Med. 23, 504–509 (2017). https://doi.org/10.1007/s11655-016-2511-4

Jun-jie Ma, Hui-ping Liu. Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 23(7):504-509(2017)
Ma, Jj., Liu, Hp. Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer., Chin. J. Integr. Med. 23, 504–509 (2017). https://doi.org/10.1007/s11655-016-2511-4 DOI：

Jun-jie Ma, Hui-ping Liu. Efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein induced by vinorelbine and cisplatin regimen in patients with non-small cell lung cancer. [J]. Chinese Journal of Integrative Medicine 23(7):504-509(2017) DOI： 10.1007/s11655-016-2511-4.

摘要

To investigate the efficacy of Aidi Injection (艾迪注射液) on overexpression of P-glycoprotein (P-gp) induced by vinorelbine and cisplatin (NP) regimen in patients with non-small cell lung cancer (NSCLC)

and study the difference between intravenous administration and targeting intratumor administration of Aidi Injection with thoracoscope. Totally 150 patients with NSCLC were randomly assigned to the control group

the intravenous group and the intratumor group by the random envelope method

50 cases in each group. The patients were treated with NP regimen (2 cycles)

NP regimen (2 cycles) plus Aidi intravenous injection

or NP regimen (2 cycles) plus Aidi intratumor injection with thoracoscope

respectively for 6 weeks. The clinical effificacy was observed based on Response Evaluation Criteria in Solid Tumors (RECIST) rules

the expression of P-gp in the tumor tissue was tested before

3 and 6 weeks after treatment

the safety was evaluated by monitoring the toxicity in the process of treatment

and the progression-free survival (PFS) was measured. Fifteen cases dropped out because of the irreconcilable conditions which had no relationship with the treatment

4 in the control group

5 in the intravenous group

and 6 in the intratumor group

respectively. Compared with the control group

the response rates (complete remission + partial response) and the disease control rates (complete remission + partial response + stable disease) were significantly higher

the P-gp expressions were significantly decreased after 3 and 6 weeks of treatment

and the Kaplan-Meier survival curves of PFS were significantly longer in the intravenous and intratumor groups (P<0.05 or P<0.01)

and the intratumor group showed better effects than the intravenous group (P<0.05 or P<0.01). Compared with the control group

the occurrences of rash

nausea and leukocytopenia were signifificantly decreased in the intravenous and intratumor groups (P<0.05)

but without signifificant difference between the intravenous and intratumor groups (P>0.05). Aidi Injection not only improves the effificacy of NP regime

but also has the function of reducing adverse events and preventing against overexpression of P-gp induced by chemotherapy of NP regimen.

Abstract

the intravenous group and the intratumor group by the random envelope method

50 cases in each group. The patients were treated with NP regimen (2 cycles)

NP regimen (2 cycles) plus Aidi intravenous injection

or NP regimen (2 cycles) plus Aidi intratumor injection with thoracoscope

respectively for 6 weeks. The clinical effificacy was observed based on Response Evaluation Criteria in Solid Tumors (RECIST) rules

the expression of P-gp in the tumor tissue was tested before

3 and 6 weeks after treatment

the safety was evaluated by monitoring the toxicity in the process of treatment

and the progression-free survival (PFS) was measured. Fifteen cases dropped out because of the irreconcilable conditions which had no relationship with the treatment

4 in the control group

5 in the intravenous group

and 6 in the intratumor group

respectively. Compared with the control group

the response rates (complete remission + partial response) and the disease control rates (complete remission + partial response + stable disease) were significantly higher

the P-gp expressions were significantly decreased after 3 and 6 weeks of treatment

and the Kaplan-Meier survival curves of PFS were significantly longer in the intravenous and intratumor groups (P<0.05 or P<0.01)

and the intratumor group showed better effects than the intravenous group (P<0.05 or P<0.01). Compared with the control group

the occurrences of rash

nausea and leukocytopenia were signifificantly decreased in the intravenous and intratumor groups (P<0.05)

but without signifificant difference between the intravenous and intratumor groups (P>0.05). Aidi Injection not only improves the effificacy of NP regime

but also has the function of reducing adverse events and preventing against overexpression of P-gp induced by chemotherapy of NP regimen.

关键词

Aidi Injectionthoracoscopynon-small cell lung cancerP-glycoproteinvinorelbine and cisplatin regimentargeting intratumor injection with thoracoscope

Keywords

Aidi Injectionthoracoscopynon-small cell lung cancerP-glycoproteinvinorelbine and cisplatin regimentargeting intratumor injection with thoracoscope

references

Berger W, Setinek U, Hollaus P, Zidek T, Steiner E, Elbling L, et al. Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications. J Cancer Res Clin Oncol 2005;131:355–363.

Zhu WY, Huang YY, Liu XG, He JY, Chen DD, Zeng F, et al. Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and topo-II proteins in non-small cell lung cancer. Anatl Rec 2012;295:208–214.

Masanek U, Pommerenke E, Mattern J, Volm M. Resistance proteins in human kidney, breast, ovarian and lung carcinoma—a comparative analysis. Oncol Reps 1995;2:41–44.

Kelly RJ, Draper D, Chen CC, Robey RW, Figg WD, Piekarz RL, et al. A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist, tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer. Clin Cancer Res 2011;17:569–580.

Hong Z, Pan LX, Chen J, Feng JF, Huang FL, Zheng XL. Traditional Chinese medicine Aidi Parenteral Solution with NP regimen for reversal of multidrug resistance in nonsmall cell lung cancer with P-gp overexpression. J Clin Med Pract (Chin) 2005;9:30–33.

Xu HX, Huang XE, Li Ying, Li CG, Tang JH. A clinical study on safety and efficacy of Aidi Injection combined with chemotherapy. Asian Pacific J Cancer Prevent 2011;12:2233–2236.

Ma WH, Duan KN, Feng M, She B, Chen Y, Zhang RM. Aidi Injection as an adjunct therapy for non-small cell lung cancer: a systematic review. J Chin Integr Med (Chin) 2009;7:315–325.

Sun XF, Pei YT, Yin QW, Wu MS, Yang GT. Application of Aidi Injection in the bronchial artery infused neo-adjuvant chemotherapy for stage III A non-small cell lung cancer before surgical operation. Chin J Integr Med 2010;16:537–541.

Travis WD, Brambilla E, Muller-Hermelink HK, eds. WHO classification of tumours. Pathology and genetics of tumours of the lung, pleura, thymus and heart. Lyon: IARC Press; 2004:26–67.

Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–1474.

Sohaib A. RECIST rules. Cancer Imaging 2012;12:345–346.

Nishino M, Jackman DM, Hatabu H, Yeap BY, Cioffredi LA, Yap JT, et al. New Response Evaluation Criteria in Solid Tumors (RECIST) guidelines for advanced non-small cell lung cancer: comparison with original RECIST and impact on assessment of tumor response to targeted therapy. Am J Roentgenol 2010;195:221–228.

Zhou DH, Lin LZ, Zhou YQ, Luo RC, Liu KF, Jia YJ, et al. Prognostic analysis of stage III–IV non-small cell lung cancer patients treated by traditional Chinese medicine. Chin J Cancer (Chin) 2005;24:1252–1256.

Ng CS, Wan IY, Yim AP. Impact of video-assisted thoracoscopic major lung resection on immune function. Asian Cardiovasc Thorac Ann 2009;17:426–432.

Kang MQ, Cao YP, Deng F, Zhu Y, Wang MH, Lin RB. Impact of intrapleural hyperthermic perfusion on immunologic reaction state of cytokines Th1/Th2 of lung carcinoma patients with malignant pleural effusion. Chin J Cancer (Chin) 2008;27:210–213.

Chen Z, Zhang M, Li X, Xu Q, Yang S. Simultaneous determination of five glycosides in Aidi Injection by RP-HPLC-ELSD. China J Chin Mater Med (Chin) 2011;36:706–708.

Li JJ, Liang S, Zhuang S, Li CY. Research progress of Adie Injection. J Changchun Univ Tradit Chin Med (Chin) 2016;32:271–273.

FULL TEXT LINK

More>

Views

Downloads

CSCD

Alert me when the article has been cited

Submit

Tools

Publicity Resources

Effects of Jianpi Jiedu Recipe (健脾解毒方) on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer

Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

Application of Response Evaluation Criteria of Traditional Chinese Medicine for Solid Tumor in advanced non-small cell lung cancer

Effect of Feitai Capsule (肺泰胶囊) on quality of life and progression-free survival of patients with unresectable non-small cell lung cancer

Related Author

No data

Related Institution

Department of Thoracic Surgery, Qilu Hospital Affiliated to Shandong University

Department of Chemistry, University of South Florida

Department of Biomedical Sciences, Cornell University, Ithaca

Department of Molecular Oncology, H. Lee Moffitt Cancer Center and Research Institute

Department of Medical Oncology, Shuguang Hospital & Putuo Hospital, Shanghai University of Traditional Chinese Medicine

Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
Tel：010-62886827, 62877592 Fax：010-62874291
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1 京公网安备11010802024621
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰